Non-Hodgkin Lymphoma | Specialty

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

February 15th 2017

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Dr. Reeder on Future Treatment Approaches in Aggressive Lymphomas

February 8th 2017

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

Upfront Ibrutinib Continues to Impress in CLL

February 3rd 2017

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Dr. Beaupre on Ibrutinib in Marginal Zone Lymphoma

February 2nd 2017

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib in patients with marginal zone lymphoma.

Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone Lymphoma

January 20th 2017

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

FDA Approves Ibrutinib for Marginal Zone Lymphoma

January 19th 2017

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

Frontline Ibrutinib Benefit Sustained in Pivotal CLL Trial Update

January 17th 2017

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

Younes Discusses Key ASH Data in MCL, DLBCL

January 13th 2017

The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.

The Future of Treatment of B-Cell Lymphoma

January 13th 2017

DLBCL: CAR-T as Curative Treatment/Bridge to Transplant

January 13th 2017

CAR-T Therapy for DLBCL

January 13th 2017

Relapsed/Refractory DLBCL

January 13th 2017

Maintenance Therapy for DLBCL

January 13th 2017

Treating High-Grade Lymphoma

January 13th 2017

Risk-Based Therapy for DLBCL

January 13th 2017

CAR-T Cell Therapies in CLL

January 13th 2017

Ibrutinib for CLL with Deletion 17p

January 13th 2017

Managing Ibrutinib Toxicity in CLL

January 13th 2017

Sequencing Therapies for Relapsed/Refractory CLL

January 13th 2017

The Role of Maintenance Therapy in CLL

January 13th 2017